Data Analytics Dashboard Clause Samples

Data Analytics Dashboard. In task T5.4 two open-source alternatives of data analytics dashboards have been developed and implemented: 1. Batch-data Visualisation Dashboard based on the Open-Source Generic Visualisation Toolbox developed in task T4.6. 2. Real-time Visualisation Dashboard based on existing open-source solutions such as Grafana. The target user of the tool are energy experts with high domain knowledge but low coding skills. Thus, the Dashboard has been defined to be intuitive and user-friendly providing a collection of reusable visualization templates/chart that can be easily integrated into customer- oriented cloud-based dashboard for predictive analytics and insights analysis. On the one hand, the Batch visualisation dashboard is an open-source dashboard based on the Generic Visualisation Toolbox developed in task T4.6. The target user of the tool are energy experts with high domain knowledge but low coding skills. Thus, an intuitive and simple Graphical User Interface (GUI) has been defined in order to configure and visualize the dashboards. On the other hand, the Real-time Dashboard visualisation dashboard is an open-source solution which integrates a series of existing open-source tools that allow users to view graphics on the screen, representations of real time data, events and process prompts, as well as historical data, offering a set of standard display panels, screens, and charts. More details about the development, functionalities and configuration of the dashboard are provided in T5.4.
View Source
Data Analytics Dashboard. Provision of Tableau software and Business Intelligence Unit support to readily access student attrition data at the course and program level based on specific filter indicators.
View Source

Related to Data Analytics Dashboard

  • Technology Research Analyst Job# 1810 General Characteristics

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Data Encryption Contractor must encrypt all State data at rest and in transit, in compliance with FIPS Publication 140-2 or applicable law, regulation or rule, whichever is a higher standard. All encryption keys must be unique to State data. Contractor will secure and protect all encryption keys to State data. Encryption keys to State data will only be accessed by Contractor as necessary for performance of this Contract.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.